Stay updated with breaking news from Iontech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.
European Commission President Ursula von der Leyen said last week at the Global Gateway Forum in Brussels that she funded a 1.2 billion euro project through which BioNTech and Univercells built modular factories in Rwanda for the production of the vaccine with messenger RNA.
Global Gateway, the European Union's euro300 billion global investment program, appears to be one in which the von der Leyens take the lion's share.
Pfizer and BioNTech announced Thursday it would soon begin a Phase 3 trial for its combined flu and COVID-19 mRNA vaccine following “positive” results from its Phase 1/2 study. Phase 1 and 2 trials are meant to evaluate whether a new drug or treatment is both safe and effective. An official for Pfizer said Thursday…
BioNTech SE (BNTX) shares are adding more than 4 percent on Tuesday morning trade after the company reported positive data for its first-in-human Phase 1/2 trial of Claudin-6, CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors.